This article is from the source 'washpo' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.washingtonpost.com/national/health-science/nih-announces-first-of-its-kind-venture-with-drug-companies-to-fight-alzheimers-diabetes/2014/02/04/2ac8f802-8d9a-11e3-95dd-36ff657a4dae_story.html?wprss=rss_homepage

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
NIH announces first-of-its-kind venture with drug companies to fight Alzheimer’s, diabetes NIH announces novel venture with drug companies to fight major diseases
(about 7 hours later)
The National Institutes of Health announced a first-of-its-kind partnership Tuesday with pharmaceutical companies and patient advocacy groups to collaborate on research aimed at treatments for Alzheimer’s, type 2 diabetes and autoimmune diseases. The National Institutes of Health is undertaking an ambitious collaboration with private industry in an attempt to speed up the search for treatments for some of the world’s most devastating diseases — Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
The pilot projects, which will last three to five years, will involve an investment of more than $230 million over five years from industry and patient advocacy groups and is unique because it will not only involve the sharing of scientists but also of data, blood samples and tissue specimens. The pilot projects announced Tuesday will involve the sharing of not only scientists but also of data, blood samples and tissue specimens among 10 rival companies, the federal government and several nonprofit groups and research foundations.
NIH Director Francis Collins said researchers involved in drug development are investing a great deal of money and time in projects and areas of research that have high rates of failure. The companies that have signed up to participate include most of the large drug makers, which in the past had resisted calls to share detailed data and samples from experiments, preferring to instead use the information to gain lucrative patents.
The agreement with NIH represents a major break from how they used to do business. The competing pharmaceutical companies have said they will hold off launching commercial ventures based on discoveries from the partnership until after the data has been made publicly available. The idea behind the collaboration is similar to that of the “open source” movement among some computer scientists who believe that sharing their code with anyone who wants it is the best way to innovate.
The first group of projects, which will last three to five years, will involve an investment of more than $230 million from industry participants including Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck, Pfizer, Sanofi and Takeda, as well as a few smaller biotech companies.
At its core, the collaboration aims to change the way biomedical research has been conducted at a fundamental level. For the most part, scientists working on new drugs still depend on trial and error, making guesses about what could work as a treatment and then testing their hypotheses.
The initiative — called the Accelerating Medicines Partnership, or AMP — takes a more comprehensive approach, bringing scientists from industry and government together to look at the universe of possibilities and prioritize the most promising targets for treatments.
NIH Director Francis S. Collins said Tuesday that researchers are investing a great deal of money and time in areas of research that have high rates of failure.
“We are going to try to increase the odds of picking the right targets to go after for the next generation of drug development,” he said. In other words, Collins said, the partnership aims to “avoid wasting precious time and money chasing duds.”“We are going to try to increase the odds of picking the right targets to go after for the next generation of drug development,” he said. In other words, Collins said, the partnership aims to “avoid wasting precious time and money chasing duds.”
While NIH has undertaken a number of collaborations with private industry in recent years, the effort announced Tuesday — called the Accelerating Medicines Partnership, or AMP for short — is the most ambitious.
The participants include many of the largest pharmaceutical companies in the world — Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Eli Lily, Merck, Pfizer, Sanofi and Takeda — as well as a few smaller biotech companies. The companies, which have long resisted calls to share detailed data and samples from experiments, have agreed to make data generated from this partnership publicly available. Scientific leaders have complained that the reluctance of the drug industry to allow their scientists to share their data has slowed the pace of research.
But the partnership is about much more than just data. At its core, AMP aims to change the way biomedical research has been conducted at a fundamental level. Scientists working on new drugs for the most part still depend on trial and error, making guesses about what could work as a treatment and then testing their hypotheses.
AMP takes a more comprehensive approach, bringing scientists from industry and government together to look at the universe of possibilities and prioritize the most promising targets for treatments.
In many ways, the project builds on the foundation of data analysis and sharing that was laid by the sequencing of the human genome in 2001.In many ways, the project builds on the foundation of data analysis and sharing that was laid by the sequencing of the human genome in 2001.
Since then, there has been an explosion of big data in three major areas of scientific research — genomics, with the cost and time to sequence DNA plummeting; proteomics, with breakthroughs in understanding of the involvement of proteins in disease; and in our ability to process, store and analyze high-resolution images. Since then, there has been an explosion of big data in three major areas of scientific research: genomics, with the cost and time to sequence DNA plummeting; proteomics, with breakthroughs in the understanding of the involvement of proteins in disease; and in the ability to process, store and analyze high-resolution images.
Despite this immense progress in basic research,there have been few breakthrough treatments for patients suffering from disease. And each year, researchers end up abandoning 99 percent of drugs that seemed promising in the early stages of research. Despite this immense progress in basic research, there have been few breakthrough treatments for patients suffering from disease. And each year, researchers end up abandoning 90 to 99 percent of drugs that seemed promising in the early stages of research.
The most painful failures happen when drugs reach so-called phase 2 and phase 3 clinical trials with patients. By that time, researchers have usually wasted years and hundreds of millions or even a billion dollars. The most painful failures happen when drugs reach “phase 2” and “phase 3” clinical trials with patients. By that time, researchers have usually spent years and hundreds of millions or even a billion dollars.
Mikael Dolsten, president of worldwide research and development at Pfizer, called the current approach for trying to find new treatments “fragmented” and said what the group is trying to develop is a “precise navigation system, a GPS for human disease.” Mikael Dolsten, president of worldwide research and development at Pfizer, called the current approach “fragmented” and said what the group is trying to develop is a “precise navigation system, a GPS for human disease.”
The partnership, the product of two years of intense negotiations between NIH officials and drug companies, aims to streamline the process of drug development at its initial stage by bringing researchers at NIH and big pharma together to sift through the very large dataset of opportunities. The partnership, the product of two years of negotiations between officials at NIH and the drug companies, aims to streamline the process of drug development at its initial stage by bringing researchers together to sift through the very large data set of opportunities in an effort to find and test new “biomarkers” for disease.
Collins said such mind-sharing and data-sharing will compress the timeline for developing new drugs and reduce costs at the same time.Collins said such mind-sharing and data-sharing will compress the timeline for developing new drugs and reduce costs at the same time.
While the first phase of the project will be focused mostly on collaborations between the industry and NIH, Robert Clarke, dean of research at Georgetown University Medical Center, said he hopes the partnership will grow to include academia. He said he believes the projects could eventually lead to a sea change in the scientific community’s attitudes toward sharing the details of research and that he imagines a day when there will be new models for those types of collaborations and new channels for funding researchers who want to build on publicly shared data.
“We have been using our limited resources to reinvent the wheel for too long,” he said.
D. Lansing Taylor, director of the University of Pittsburgh’s Drug Discovery Institute, said the announcement comes at a time of increasing pressure on pharmaceutical companies’ finances. With the patents for many of the industry’s blockbuster drugs expired or expiring and a controversy simmering over toxicity issues related to some new therapies, drug makers are seeking new ways of doing business.
“Collaboration is a necessity. It’s not an option anymore,” Taylor said. “It’s too expensive to develop and utilize the new technologies on your own.”